In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular), Method - Global Forecast to 2018
NEW YORK, April 14, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular), Method - Global Forecast to 2018
http://www.reportlinker.com/p02076244/In-Vitro-Toxicology/-Toxicity-Testing-Market-by-Industry-Diagnostic-Pharmaceutical-Cosmetics-Chemical-Technology-Cell-Culture-HTS-Omics-Applications-Systemic-Dermal-Ocular-Method---Global-Forecast-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
Attributed to the support offered by the European government, the in vitro toxicology testing market in Europe was the largest in 2013 and is expected to hold the same stance by 2018
There has been a substantial rise in the costs to develop a new pharmaceutical product in recent years. This is specially observed when a new compound enters animal testing and clinical trials. The use of animals in experimentation is becoming dearer, primarily due to the costs involved in breeding and acquisition of animals, due to the complexity of procedures involved in the in vivo testing, and several other ethical issues including concerns for animal welfare. Moreover the rates of drug attrition have also risen in recent years due to lesser availability of data on the toxicity profiles of the candidates that are under development process. To counteract these issues there has been a rise in the development of in vitro methods that are alternative to animal testing. A paradigm shift is observed towards emerging technologies such as assays based on human cells or non-mammalian models, high throughput testing, omics approaches, ex vivo models, and in silico techniques.
Pharmaceutical industry was the largest segment in the in vitro toxicology testing market which is expected to hold the leading position in the coming five years. This is largely attributed to the widely recognized factors of evaluation of the toxicity levels in the early stages of development that necessitates the use of in vitro methods to improve the drug toxicity profiles. On the other hand, cosmetic industry will be the fastest growing industry in the coming years as a result of the huge government support in Europe to ban the use of animals for testing the toxic effects of beauty products. The European government has also forbidden the marketing of those cosmetics product which were tested on animals.
For better interpretation of in vitro results cell culture technology involving cell based assays has emerged as a momentous technology that has been driving the in vitro toxicology testing market. With the advancement in the cell culture technology a number of cell models are emerging that provide insights into the biochemical and signaling process that better interprets the in vitro data. With the increasing demand of emergent 3D models the cell culture technology is estimated to be the fastest growing technology in the next five years.
With the implementation of several laws through adoption of various initiatives by the European government to stop animal testing; the European region is the leading market. The government promotes the use of in vitro techniques through launch of programs such as AXLR8 for the purpose of monitoring EU funded 3Rs research activities with the aim of accelerating the transition from in vivo testing to in vitro testing. The emerging countries in Asia such as China and India will register high growth in the coming years, this can be attributed to the low development costs offered by these nations. Moreover due to the economic growth of these nations there has been a rise in the investments in these countries which is further propelling the market in a positive direction.
The grey area while estimating the market size was the overlapping nature of the applications while segregating them based on evaluation of endpoints involved. These included testing of end points such as acute systemic toxicity, pharmacokinetics & metabolism, repeated dose/organ toxicity under systemic toxicity, dermal penetration, skin irritation/corrosion and skin sensitization under dermal toxicity. This was later clarified with the help of various experts that participated during the study.
From an insight perspective, this research report focuses on the qualitative data, market size, share, growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market shares, sizes, and related growth of various segments in the industry. It also focuses on the emerging and high-growth segments of in vitro toxicology testing market, high-growth regions, and the initiatives of respective governments.
The competitive landscape covers the growth strategies adopted by industry players in the last three years. The company profiles comprise the basic views on the key players in the in-vitro toxicology testing market, product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 REPORT DESCRIPTION 21
1.3 MARKETS COVERED 24
1.4 STAKEHOLDERS 25
1.5 MARKET SCOPE 26
1.6 RESEARCH METHODOLOGY 26
1.6.1 MARKET SIZE ESTIMATION & DATA TRIANGULATION 27
1.6.2 KEY DATA POINTS FROM SECONDARY SOURCES 31
1.6.3 KEY DATA POINTS FROM PRIMARY SOURCES 31
1.6.4 ASSUMPTIONS 33
2 EXECUTIVE SUMMARY 34
3 PREMIUM INSIGHTS 40
3.1 IN-VITRO TOXICOLOGY TESTING MARKET SIZE 40
3.2 MARKET DYNAMICS 41
3.3 IN-VITRO TOXICOLOGY TESTING MARKET SIZE SNAPSHOT 42
3.4 IN-VITRO TOXICOLOGY TESTING, GEOGRAPHIC ANALYSIS BY INDUSTRY 43
3.5 IN-VITRO TOXICOLOGY TESTING MARKET SIZE,
BY TECHNOLOGY 44
3.6 IN-VITRO TOXICOLOGY TESTING MARKET SIZE,
BY METHOD 45
3.7 IN-VITRO TOXICOLOGY TESTING MARKET,
BY APPLICATION 46
4 MARKET OVERVIEW 47
4.1 INTRODUCTION 48
4.2 MARKET SEGMENTATION 49
4.3 MARKET DYNAMICS 51
4.3.1 DRIVERS 51
4.3.1.1 Dearth of publicly accessible databases to facilitate the use of in vitro test methods 51
4.3.1.2 New and promising technologies to propel the in vitro toxicology testing market 52
4.3.1.3 Technological advancements and shifting focus to innovative approaches of 3D cell cultures are driving the cell culture technology market 52
4.3.1.4 Opposition to animal testing will help shift the focus to in vitro testing 53
4.3.2 RESTRAINTS 53
4.3.2.1 Technological disadvantages associated with in vitro tests limit their use 53
4.3.2.2 In vitro models cannot detect autoimmunity and immunostimulation 54
4.3.2.3 Predictive ability of in vitro testing leads to decreasing adoption of these tests 54
4.3.3 OPPORTUNITIES 55
4.3.3.1 The Toxicology in the 21st Century (Tox21) program 55
4.3.3.2 Increasing drug discovery and innovation and modernization in the in vitro toxicity testing market 55
4.3.3.3 Growing demand for in vitro toxicology in the European market 56
4.3.4 THREATS 56
4.3.4.1 Reluctance of regulatory authorities to consider alternate methods for proving safety and efficacy 56
4.4 BURNING ISSUES 57
4.4.1 VALIDATION OF NEW IN VITRO METHODS 57
4.4.2 DIFFERENCES IN OPINION BETWEEN THE U.S. AND EU REGULATORY AUTHORITIES 57
4.5 WINNING IMPERATIVES 59
4.5.1 3D HUMAN HEPATOCYTE MODELS TO BOOST THE IN VITRO TESTING MARKET 59
5 TOXICOLOGY TESTING MARKET, BY INDUSTRY 60
5.1 INTRODUCTION 61
5.2 DIAGNOSTICS 64
5.2.1 DIAGNOSTICS, BY TYPE 64
5.2.1.1 Forensics 65
5.2.1.2 Drug abuse & workplace drug testing 67
5.2.2 DIAGNOSTICS, BY SAMPLE 69
5.2.2.1 Urine screening 70
5.2.2.2 Alcohol screening 71
5.2.2.3 Oral fluid screening 73
5.2.2.4 Hair screening 75
5.2.2.5 Others 76
5.3 COSMETICS & HOUSEHOLD PRODUCTS 77
5.4 PHARMACEUTICAL INDUSTRY 80
5.5 CHEMICALS INDUSTRY 82
5.6 FOOD INDUSTRY 84
6 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 86
6.1 INTRODUCTION 87
6.1.1 CELL CULTURE TECHNOLOGY 89
6.1.1.1 Primary monolayer and three-dimensional cell cultures 92
6.1.2 HIGH THROUGHPUT TECHNOLOGIES 93
6.1.2.1 High throughput toxicity testing 96
6.1.2.2 The EPA ToxCast program 97
6.1.3 MOLECULAR IMAGING TECHNOLOGIES 97
6.1.3.1 Molecular imaging technologies 99
6.1.3.2 High content imaging technologies 101
6.1.4 OMICS TECHNOLOGIES 102
6.1.4.1 Genomics 104
6.1.4.2 Toxicogenomics 105
6.1.4.3 Proteomics 106
6.1.4.4 Metabolomics 107
7 IN VITRO TOXICITY TESTING MARKET, BY APPLICATION 108
7.1 INTRODUCTION 109
7.2 SYSTEMIC TOXICITY 111
7.3 DERMAL TOXICITY 113
7.4 OCULAR TOXICITY 115
7.5 ENDOCRINE DISRUPTION (REPRODUCTIVE/DEVELOPMENTAL TOXICITY) 117
7.6 OTHERS (ADMET, ORGAN-SPECIFIC TOXICITY,
DRUG-DRUG INTERACTIONS, TARGET/PATHWAY ASSAYS, & ECOTOXICITY) 119
7.6.1 ADMET (PHARMACOKINETICS & METABOLISM TESTING) 120
7.6.2 ORGAN-SPECIFIC TOXICITY 121
7.6.3 DRUG-DRUG INTERACTIONS 121
7.6.4 TARGET/PATHWAY ASSAYS 122
7.6.5 ECOTOXICITY 123
8 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD 124
8.1 INTRODUCTION 125
8.2 CELLULAR ASSAYS 127
8.3 BIOCHEMICAL ASSAYS 130
8.4 IN SILICO METHODS 132
8.5 EX VIVO MODELS 135
9 GEOGRAPHIC ANALYSIS 137
9.1 INTRODUCTION 138
9.2 EUROPE 140
9.3 NORTH AMERICA 148
9.4 ASIA 155
9.5 REST OF THE WORLD (ROW) 162
10 COMPETITIVE LANDSCAPE 168
10.1 INTRODUCTION 168
10.2 IN VITRO TOXICOLOGY TESTING MARKET, COMPETITIVE LANDSCAPE, 2011-MARCH 2014 169
10.3 NEW PRODUCT LAUNCHES 170
10.4 MERGERS & ACQUISITIONS 175
10.5 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 179
10.6 EXPANSIONS 186
10.7 OTHER DEVELOPMENTS 189
11 COMPANY PROFILES 191 (Overview, Products & Services, Strategy, & Developments)*
11.1 AGILENT TECHNOLOGIES, INC. 191
11.2 ALERE, INC. 196
11.3 BIO-RAD LABORATORIES, INC. 200
11.4 BIORELIANCE, INC.
(A SUBSIDIARY OF SIGMA-ALDRICH CORPORATION) 205
11.5 CATALENT 208
11.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 213
11.7 COVANCE, INC. 217
11.8 CYPROTEX 223
11.9 EUROFINS SCIENTIFIC 228
11.10 GE HEALTHCARE 232
11.11 LIFE TECHNOLOGIES CORPORATION (THERMO FISHER SCIENTIFIC) 236
11.12 QUEST DIAGNOSTICS 242
*Details on Overview, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
LIST OF TABLES
TABLE 1 IN-VITRO TOXICOLOGY/TOXICITY TESTING, BY GEOGRAPHY,
2011-2013 ($MILLION) 38
TABLE 2 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2011–2018 ($MILLION) 62
TABLE 3 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY TYPE, 2011–2018 ($MILLION) 64
TABLE 4 IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY GEOGRAPHY, 2011–2018 ($MILLION) 65
TABLE 5 IN VITRO TOXICOLOGY TESTING MARKET FOR FORENSICS,
BY GEOGRAPHY, 2011–2018 ($MILLION) 67
TABLE 6 IN VITRO TOXICOLOGY TESTING MARKET FOR DRUG ABUSE & WORKPLACE DRUG TESTING, BY GEOGRAPHY, 2011–2018 ($MILLION) 68
TABLE 7 IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY SAMPLE, 2011–2018 ($MILLION) 70
TABLE 8 URINE SAMPLE TESTING MARKET, BY GEOGRAPHY,
2011–2018 ($MILLION) 71
TABLE 9 ALCOHOL SAMPLE TESTING MARKET, BY GEOGRAPHY,
2011–2018 ($MILLION) 73
TABLE 10 ORAL SAMPLE TESTING MARKET, BY GEOGRAPHY,
2011–2018 ($MILLION) 74
TABLE 11 HAIR SAMPLE TESTING MARKET, BY GEOGRAPHY,
2011–2018 ($MILLION) 75
TABLE 12 OTHERS SAMPLE TESTING MARKET, BY GEOGRAPHY,
2011–2018 ($MILLION) 76
TABLE 13 IN VITRO TOXICOLOGY TESTING MARKET FOR COSMETICS & HOUSEHOLD INDUSTRY, BY GEOGRAPHY, 2011–2018 ($MILLION) 79
TABLE 14 IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY GEOGRAPHY, 2011–2018 ($MILLION) 81
TABLE 15 IN VITRO TOXICOLOGY TESTING MARKET FOR CHEMICAL INDUSTRY, BY GEOGRAPHY, 2011–2018 ($MILLION) 83
TABLE 16 IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY,
BY GEOGRAPHY, 2011–2018 ($MILLION) 85
TABLE 17 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2011–2018 ($MILLION) 89
TABLE 18 IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE TECHNOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLION) 90
TABLE 19 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE TECHNOLOGY, BY INDUSTRY, 2011–2018 ($MILLION) 91
TABLE 20 IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH THROUGHPUT TECHNOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLION) 94
TABLE 21 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH THROUGHPUT TECHNOLOGY, BY INDUSTRY, 2011–2018 ($MILLION) 95
TABLE 22 IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR IMAGING TECHNOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLION) 98
TABLE 23 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR IMAGING TECHNOLOGY, BY INDUSTRY, 2011–2018 ($MILLION) 99
TABLE 24 IN VITRO TOXICOLOGY TESTING MARKET FOR OMICS TECHNOLOGIES, BY GEOGRAPHY, 2011–2018 ($MILLION) 103
TABLE 25 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET FOR OMICS TECHNOLOGIES, BY INDUSTRY, 2011–2018 ($MILLION) 104
TABLE 26 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2011–2018 ($MILLION) 110
TABLE 27 IN VITRO TOXICOLOGY TESTING MARKET FOR SYSTEMIC TOXICOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLION) 112
TABLE 28 IN VITRO TOXICOLOGY TESTING MARKET FOR DERMAL TOXICOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLLION) 114
TABLE 29 IN VITRO TOXICOLOGY TESTING MARKET FOR OCULAR TOXICOLOGY, BY GEOGRAPHY, 2011–2018 ($MILLLION) 116
TABLE 30 IN VITRO TOXICOLOGY TESTING MARKET FOR ENDOCRINE DISRUPTION, BY GEOGRAPHY, 2011–2018 ($MILLLION) 118
TABLE 31 IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2011–2018 ($MILLLION) 119
TABLE 32 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2011–2018 ($MILLION) 126
TABLE 33 PRIMARY CELL CULTURE ADVANTAGES & LIMITATIONS 127
TABLE 34 IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS,
BY GEOGRAPHY, 2011–2018 ($MILLION) 129
TABLE 35 IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY GEOGRAPHY, 2011–2018 ($MILLION) 131
TABLE 36 IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO METHODS,
BY GEOGRAPHY, 2011–2018 ($MILLION) 133
TABLE 37 IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO METHODS,
BY GEOGRAPHY, 2011–2018 ($MILLION) 135
TABLE 38 IN VITRO TOXICITY MARKET, BY GEOGRAPHY, 2011–2018 ($MILLION) 139
TABLE 39 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2011–2018 ($MILLION) 142
TABLE 40 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY SAMPLE, 2011–2018 ($MILLION) 143
TABLE 41 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY TYPE, 2011–2018 ($MILLION) 144
TABLE 42 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2011–2018 ($MILLION) 145
TABLE 43 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD,
2011–2018 ($MILLION) 146
TABLE 44 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2011–2018 ($MILLION) 147
TABLE 45 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET,
BY INDUSTRY, 2011–2018 ($MILLION) 149
TABLE 46 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY SAMPLE, 2011–2018 ($MILLION) 150
TABLE 47 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY TYPE, 2011–2018 ($MILLION) 151
TABLE 48 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET,
BY TECHNOLOGY, 2011–2018 ($MILLION) 152
TABLE 49 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET,
BY METHOD, 2011–2018 ($MILLION) 153
TABLE 50 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET,
BY APPLICATION, 2011–2018 ($MILLION) 154
TABLE 51 ASIA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY,
2011–2018 ($MILLION) 157
TABLE 52 ASIA: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY SAMPLE, 2011–2018 ($MILLION) 158
TABLE 53 ASIA: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY TYPE, 2011–2018 ($MILLION) 159
TABLE 54 ASIA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2011–2018 ($MILLION) 159
TABLE 55 ASIA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD,
2011–2018 ($MILLION) 160
TABLE 56 ASIA: IN VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2011–2018 ($MILLION) 161
TABLE 57 ROW: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY,
2011–2018 ($MILLION) 163
TABLE 58 ROW: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY SAMPLE, 2011–2018 ($MILLION) 164
TABLE 59 ROW: IN VITRO TOXICOLOGY TESTING MARKET FOR DIAGNOSTICS INDUSTRY, BY TYPE, 2011–2018 ($MILLION) 165
TABLE 60 ROW: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2011–2018 ($MILLION) 165
TABLE 61 ROW: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD,
2011–2018 ($MILLION) 166
TABLE 62 ROW: IN VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2011–2018 ($MILLION) 167
TABLE 63 NEW PRODUCT LAUNCHES, 2011–2014 170
TABLE 64 MERGERS & ACQUISITIONS, 2011–2014 175
TABLE 65 AGREEMENTS, PARTNERSHIPS, & COLLABORATIONS, 2011–2014 179
TABLE 66 EXPANSIONS, 2011–2014 186
TABLE 67 OTHER DEVELOPMENTS, 2011–2014 189
LIST OF FIGURES
FIGURE 1 MARKET CRACKDOWN & DATA TRIANGULATION FOR THE IN VITRO TOXICOLOGY TESTING MARKET 29
FIGURE 2 MARKET FORECASTING MODEL 30
FIGURE 3 IN VITRO TOXICOLOGY TESTING, BY INDUSTRY, 2013 ($MILLION) 35
FIGURE 4 GLOBAL IN VITRO TOXICOLOGY TESTING, BY TECHNOLOGY,
2013 ($MILLION) 37
FIGURE 5 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE, ($MILLION) 40
FIGURE 6 GLOBAL IN-VITRO TOXICOLOGY TESTING, MARKET DYNAMICS 41
FIGURE 7 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE SNAPSHOT, 2013 ($MILLION) 42
FIGURE 8 IN-VITRO TOXICOLOGY TESTING, GEOGRAPHIC ANALYSIS,
BY INDUSTRY, 2013 ($MILLION) 43
FIGURE 9 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET SIZE,
BY TECHNOLOGY, 2013 ($MILLION) 44
FIGURE 10 GLOBAL IN-VITRO TOXICOLOGY TESTINGMARKET SIZE, BY METHOD, 2013 ($MILLION) 45
FIGURE 11 OPPORTUNITY MATRIX: GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2013 46
FIGURE 12 MARKET CRACKDOWN & DATA TRIANGULATION FOR THE IN VITRO TOXICOLOGY TESTING MARKET 50
FIGURE 13 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY,
2013 ($MILLION) 61
FIGURE 14 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2013 VS 2018 ($MILLION) 87
FIGURE 15 PRIMARY CELL CULTURES ADVANTAGES & DISADVANTAGES 93
FIGURE 16 HIGH THROUGHPUT TECHNOLOGY ADVANTAGES & DISADVANTAGES 96
FIGURE 17 MOLECULAR IMAGING TECHNOLOGIES ADVANTAGES & DISADVANTAGES 100
FIGURE 18 HIGH CONTENT IMAGING TECHNOLOGIES ADVANTAGES & DISADVANTAGES 101
FIGURE 19 GENOMICS ADVANTAGES & DISADVANTAGES 105
FIGURE 20 PROTEOMICS ADVANTAGES & DISADVANTAGES 106
FIGURE 21 METABOLOMICS ADVANTAGES & DISADVANTAGES 107
FIGURE 22 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY APPLICATION, 2013 ($MILLION) 109
FIGURE 23 OPPORTUNITY MATRIX: GLOBAL IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2013 125
FIGURE 24 IN VITRO TOXICOLOGY TESTING MARKET, BY GEOGRAPHY, 2013 138
FIGURE 25 KEY GROWTH STRATAGIES, 2011–MARCH 2014 169
To order this report: In-Vitro Toxicology/ Toxicity Testing Market by Industry (Diagnostic, Pharmaceutical, Cosmetics, Chemical), Technology (Cell Culture, HTS, Omics), Applications (Systemic, Dermal, Ocular), Method - Global Forecast to 2018
http://www.reportlinker.com/p02076244/In-Vitro-Toxicology/-Toxicity-Testing-Market-by-Industry-Diagnostic-Pharmaceutical-Cosmetics-Chemical-Technology-Cell-Culture-HTS-Omics-Applications-Systemic-Dermal-Ocular-Method---Global-Forecast-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article